Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

• 主要な著者: Shatha M. Alobaid (著者), Rahaf M. Alshahrani (著者), Asma S. Alonazi (著者), Nawal M. Alrasheed (著者), Maha A. Alamin (著者), Tahani K. Alshammari (著者), Anfal F. Bin Dayel (著者), Doaa M. Elnagar (著者), Rana R. Alotaibi (著者), Lama A. Almuthnabi (著者), Dalia H. Almasud (著者), Shahad E. Al-Ammar (著者), Shahad O. Almadhi (著者), Reema A. Almalke (著者), Nouf T. Aldamri (著者), Hanan K. Alghibiwi (著者), Dalal A. Alkhelb (著者), Nouf M. Alrasheed (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2024-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin...